HG-7-86-01

SKU: orb2566109

Description

HG-7-86-01 is a type II, potent, and selective tyrosine kinase inhibitor designed to target the drug-resistant Bcr-Abl T315I mutant in chronic myeloid leukemia (CML). It demonstrates robust antiproliferative effects in vitro and has shown efficacy in preclinical CML models, supporting its use as a valuable research tool in oncology and kinase inhibitor development.

Research Area

Cardiovascular Research, Signal Transduction

Key Properties

• CAS Number: 1258391-14-8
• MW: 562.57
• Purity: 99.07%
• Formula: C₂₈H₂₁F₃N₆O₂S
• SMILES: O=C(NC=1C=C(C=C(C1)C(F)(F)F)N2C=NC(=C2)C)C3=CC=CC(=C3)C4=NC=5SC(=NC5C=C4)NC(=O)C6CC6
• Target: Bcr-Abl
• Solubility: DMSO:2 mg/mL (3.56 mM)

Bioactivity

• In Vitro:
  HG-7-86-01 exhibits antiproliferative activity across multiple cell lines harboring mutant FLT3: Ba/F3-FLT3-ITD: IC₅₀ = 125–250 nM Ba/F3-Y572C: IC₅₀ = 12.5–25 nM Ba/F3-N841I: IC₅₀ = 200–400 nM Ba/F3-D835Y: IC₅₀ = 500–1000 nM

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Compound Identifiers

PubChem CID

49838489